🔹 EPS: $6.64 (Est. $7.78) 🔴; DOWN -2% YoY
🔹 Revenue: $65.65B (Est. $62.91B) 🟢; UP +28% YoY
🔹 Net Income: $1.42B (Est. $2.18B); UP +38% YoY
🔹 SG&A Expense Ratio: 5.9% (Prev. 7.9%) 🟢
FY25 Outlook:
🔹 EPS: At least $29.50 (Est. $31.30) 🔴
🔹 Revenue: At least $252.0B (Est. $251.2B) 🟡
🔹 Adjusted Income from Operations: At least $7.9B
🔹 Adjusted SG&A Expense Ratio: ~5.4%
🔹 Operating Cash Flow: ~$10.0B
🔹 Dividend Per Share: Increased 8% to $1.51 per share
Q4 Segment Performance:
Evernorth Health Services:
🔹 Revenue: $53.74B; UP +33% YoY
🔹 Pharmacy Benefit Services Revenue: $30.27B; UP +47% YoY
🔹 Specialty & Care Services Revenue: $23.47B; UP +18% YoY
🔹 Adjusted Income from Operations (Pre-Tax): $2.15B; UP +14% YoY
🔸 Growth driven by client wins, strong specialty volume, and Humira biosimilar adoption.
Cigna Healthcare:
🔹 Revenue: $13.33B (Est. $13.01B) 🟢; UP +3% YoY
🔹 Adjusted Income from Operations (Pre-Tax): $511M (Prev. $969M) 🔴; DOWN -47% YoY
🔹 Medical Care Ratio (MCR): 87.9% (Prev. 82.2%) 🔴
🔹 Total Medical Customers: 19.15M (Prev. 19.78M) 🔴
🔸 Decline driven by higher stop-loss medical costs, partially offset by premium rate increases.
Segment Projections:
🔹 Evernorth Adjusted Income from Operations (Pre-Tax): At least $7.2B
🔹 Cigna Healthcare Adjusted Income from Operations (Pre-Tax): At least $4.1B
🔹 Cigna Healthcare MCR: 83.2%-84.2%
🔹 Total Medical Customers: ~18.1M
Key Business Highlights:
🔸 Cigna is divesting its Medicare businesses to HCSC, expected to close in Q1 FY25.
🔸 Evernorth continues to expand specialty and care services with strong organic growth.
🔸 Share repurchase authorization increased by $6B, bringing the total to $10.3B.
🔸 Cigna is implementing corrective actions to address stop-loss cost pressures.